Home Xeljanz Lawsuits

Xeljanz Lawsuits

People may be eligible to file Xeljanz lawsuits if they or a loved one took the drug for rheumatoid arthritis, psoriatic arthritis or ulcerative colitis and suffered blood clots, cardiovascular problems or cancer. FDA safety alerts in 2019 and 2021 warned that Xeljanz may increase the risk of blood clots, heart problems, death and cancer.

This is an active lawsuit
See if you can file

See If You Qualify for Legal Action

You may be legally entitled to compensation for your injuries. Get a free case review today to find out if you are eligible.

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. After submitting, you will be contacted by one of Drugwatch's trusted legal partners. This is legal advertising.
Last Modified: April 29, 2021
Fact Checked
Fact-Checked

Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Lawyers are currently accepting cases from rheumatoid arthritis, psoriatic arthritis and ulcerative colitis patients who took Xeljanz or Xeljanz XR and suffered a blood clot in the legs, thigh or pelvis, or in the lungs. The medical term for blood clots in the lungs is pulmonary embolism, or PE. Doctors refer to the other type of clots as deep vein thrombosis, or DVT.

The U.S. Food and Drug Administration first approved Xeljanz in 2012 to treat moderately to severely active rheumatoid arthritis. It later approved the drug for ulcerative colitis and psoriatic arthritis.

The drug has been on the market for years, but in February 2019, the FDA released a safety alert about an increased risk of blood clots and death. The agency has since approved a black box warning about the risks.

According to the Xeljanz website, about 132,000 Americans were prescribed the drug between January 2013 and July 2018 to treat rheumatoid arthritis. Many more patients may have been prescribed the medication it to treat ulcerative colitis or psoriatic arthritis. Pfizer reported it made about $1.7 billion off the drug in 2018.

Blood Clots

After the FDA announced an increased risk of clots with Xeljanz, lawyers began accepting cases on behalf of people who took the drug and suffered from two kinds of blood clots: pulmonary embolisms and deep vein thrombosis.

Between 2013 and 2018, the FDA received reports of 52 DVTs and 79 PEs in patients who took Xeljanz, according to the FDA Adverse Events Reporting System (FAERS) Public Dashboard. Patients in 15 of the cases died.

The limitation of FAERS is that data is self-reported, and there is no way to verify these results. There may also be more cases than were reported.

Fact
From 2013 to 2018, the FDA received 52 reports of DVTs and 79 reports of PEs related to Xeljanz. Fifteen of the patients died.

Pulmonary embolisms are dangerous blood clots that travel to the lungs. People who suffer from PEs may have irregular heartbeat, chest pain and trouble breathing. They may faint or feel lightheaded, or cough up blood. PEs require immediate medical attention.

DVTs may cause pain, swelling, tenderness and redness in the part of the body where the blood clot formed or traveled.

These blood clots can be life threatening. Patients who suffer these symptoms should seek medical attention.

Doctors may treat clots with medication, compression stockings or surgery. Some people may have to be on medications for the rest of their lives to prevent future clots.

Lawsuits against Pfizer may seek compensation for medical bills incurred from DVT or PE treatment.

Did you suffer blood clots, cardiovascular problems or cancer after taking Xeljanz?

Clinical Trial Finds Increased Risk of Clots

When the FDA originally approved Xeljanz, it required an additional safety study to gauge the cardiovascular safety of the drug. This post-marketing safety study, called A3921133, is ongoing.

On Feb. 19, 2019, Pfizer announced in a press release that it would transition rheumatoid arthritis study patients who were on 10 mg of tofacitinib twice daily to 5 mg of tofacitinib twice daily. The company made this decision after the tofacitinib Rheumatology Data Safety Monitoring Board flagged a safety problem with the 10 mg twice daily treatment group.

Fact
Pfizer’s post-marketing clinical study found people with rheumatoid arthritis who took Xeljanz at 10 mg twice daily had an increased risk of pulmonary embolism and death.

The safety monitoring board found people who had taken 10 mg of tofacitinib twice daily for rheumatoid arthritis had a “statistically and clinically important difference” in the rate of pulmonary embolism and overall death compared to people who had taken 5 mg of tofacitinib twice daily or another drug called a tumor necrosis factor inhibitor.

Despite reports of DVTs and PEs in FAERS from 2013 to 2018, Pfizer said it found no results similar to those in the study.

“Similar results to study A3921133 have not been identified in Pfizer analyses of other tofacitinib RA clinical trials or routine monitoring of post-marketing safety data, including our statistical analyses of the FDA Adverse Event Reporting System database,” Pfizer said in its press release.

On Feb. 25, 2019, the FDA released a safety communication to alert the public that the safety trial found an increased risk of PE and death. Three days later, Pfizer sent a letter advising health care providers of the risk.

In July 2019, the FDA approved a black box warning about an increased risk of blood clots and death in people with RA who are 50 years old or older and have at least one cardiovascular risk factor. Though the data found these risks in people with RA, the agency has said people who use the drug for ulcerative colitis may also be at risk.

Cardiovascular Problems

In February 2021, the FDA issued a Drug Safety Communication alerting the public that initial safety trial results linked Xeljanz to an increased risk of serious cardiovascular events.

The most reported cardiovascular event in trials was heart attack, according to Pfizer’s January 2021 press release.

Cardiovascular events linked to Xeljanz and lawsuits include:
  • Cardiac arrest
  • Cardiovascular death
  • Congestive heart failure
  • Coronary revascularization
  • Myocardial infarction

Cancer

The current Xeljanz black box warning from 2019 warns about an increased risk of lymphoma and other cancers.  In February 2021, the FDA released a Drug Safety Communication warning that initial data from safety trials signaled an increased risk of cancer.

The most commonly reported cancer in those who took Xeljanz was lung cancer, according to Pfizer’s January 2021 press release.

Cancers linked to Xeljanz and lawsuits include:
  • Breast cancer
  • Colon cancer
  • Lung cancer
  • Non-Hodgkin’s lymphoma
  • Prostate cancer
Please seek the advice of a medical professional before making health care decisions.
Related Pages